Figure 1
Figure 2
Figure 3
Figure 4
The demographic data, average nodule size, standardized uptake value (SUVmax), metabolic parameter relating to the pulmonary nodules through dynamic 18F-FDG PET/CT, and perfusion parameters through perfusion CT for the benign and malignant nodules
| Benign Nodules | Malignant Nodules | p value | |
|---|---|---|---|
| Total Number of nodules | 9 | 12 | |
| Number of male patients (%) | 5/9 (55 %) | 6/12 (50 %) | |
| Average patient age (years ± SD) | 63 ± 7.5 | 68 ± 6.7 | |
| Average nodule size, range (mm) | 18, 9–29 | 22, 12–30 | |
| Average SUVmax 18F-FDG PET/CT ± SD | 2.2 ± 1.7 | 7.0 ± 4.5 | 0.0148 |
| Number of nodules analysed for dynamic 18F-FDG PET/CT | 7 | 9 | |
| Average Ki ± SD (min-1) | 0.0057 ± 0.0071 | 0.0230 ± 0.0155 | 0.0311 |
| Number of nodules analysed for perfusion CT parameters | 7 | 10 | |
| Average BV ± SD (Patlak, ml/100ml) | 11.6857 ± 6.7347 | 28.3400 ± 15.9672 | 0.0250 |
| Average AF ± SD (ml/100g/min) | 74.4571 ± 89.0321 | 89.2000 ± 49.8883 | 0.1613 |
Comparison of the diagnostic accuracy of different techniques and parameters with pre-specified and derived cut-point values for malignancy
| Parameter | Cut-point value/grade | Sensitivity (95% CI) | Specificity (95% CI) | Accuracy | |
|---|---|---|---|---|---|
| SUVmax | Pre-specified | ≥ 2.5* | 75.0% (46.8 to 91.1%) | 66.7% (35.4 to 87.9%) | 71.4% |
| SURBLOOD | Pre-Derived specified | ≥ 1.56 | 83.3% (55.2 to 97.0%) | 88.9% (56.5 to 99.4%) | 85.7% |
| SURLIVER | Pre-specified | ≥ 1.12 | 83.3% (55.2 to 97.0%) | 66.7% (35.4 to 87.9%) | 76.2% |
| SUV grade | Pre-specified & Derived | ≥ 3 | 66.7% (39.0 to 86.2%) | 77.8% (45.3 to 96.0%) | 71.4% |
| Ki | Derived | ≥ 0.01 min-1 | 77.8% (45.2 to 96.0%) | 85.7% (48.7 to 99.3%) | 81.3% |
| BV | Derived | ≥ 21 ml/100ml | 70% (39.7 to 89.2%) | 100% (64.6 to 100%) | 82.4% |
| AF | Derived | ≥ 65 ml/100g/min | 70% (39.7 to 89.2%) | 85.7% (48.7 to 99.3%) | 76.5% |